Pethidine, known as meperidine in the United States, carries a genuine risk of addiction that has played a central role in its declining use worldwide. Once considered a safer alternative to morphine, pethidine proved to be just as habit-forming while also producing a toxic metabolite that makes chronic use uniquely dangerous. The combination of its euphoric effects, fast onset, and serious complications during long-term use has led many hospitals to remove it from their formularies entirely, though it remains available in some settings and continues to cause dependency in patients and healthcare workers alike.
How Pethidine Works and Why It Hooks People
Pethidine is a synthetic opioid that binds to mu-opioid receptors in the brain, producing pain relief, sedation, and the warm rush of euphoria common to drugs in this class. Its onset is rapid when injected, typically within minutes, and its effects wear off faster than morphine’s. That quick peak and relatively short duration create a cycle where users feel the drug working almost immediately but need another dose sooner, a pattern that reinforces repeated use and accelerates dependence.
What sets pethidine apart from many other opioids is its activity beyond the opioid receptor. The drug inhibits the serotonin transporter at concentrations close to those seen in patients’ blood during normal dosing, and it also interacts directly with serotonin receptors.1PubMed Central. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome This serotonergic activity means pethidine can produce mood-altering effects that go beyond typical opioid euphoria. Some researchers believe this dual action on opioid and serotonin pathways may contribute to the subjective “high” that users describe as distinctive from other opioids, which could partly explain why some people develop a specific preference for pethidine over alternatives.
Tolerance Develops Quickly
One of the most troubling features of pethidine use is how fast tolerance builds. In animal studies, the painkilling effect of pethidine diminished significantly by the fourth and fifth days of regular dosing, to the point where it was no longer distinguishable from a placebo injection.2PLOS ONE. Chronopharmacodynamics and Chronopharmacokinetics of Pethidine in Mice While human tolerance timelines vary with dose and individual biology, the clinical picture is consistent: patients and users find they need escalating doses to get the same relief or the same high.
This rapid tolerance creates a dangerous escalation pattern. A person who starts with a standard clinical dose of 50 to 100 milligrams may, within weeks, be using several times that amount. One documented case of iatrogenic addiction, where the dependence was caused by medical treatment, saw a patient escalate to 150 milligrams every four hours with additional rescue doses, maintaining that level for 80 days.3International Archives of Addiction Research and Medicine. Iatrogenic Addiction Caused by Meperidine At those doses, the toxic metabolite norpethidine accumulates to dangerous levels, and the person faces both the misery of opioid dependence and the physical harm of a drug that is actively poisoning their nervous system.
The Norpethidine Problem
When your liver breaks down pethidine, one of the products is norpethidine (also called normeperidine), a compound with significant nervous system toxicity.4The Journal of Emergency Medicine. Meperidine: Therapeutic use and toxicity Unlike pethidine itself, which clears the body in a few hours, norpethidine lingers much longer, with a half-life that can stretch beyond 15 hours in healthy individuals and far longer in anyone whose kidneys are not working well.5PubMed. Pharmacokinetics of opioids in renal dysfunction
This metabolite does not just tag along quietly. Norpethidine is a stimulant rather than a depressant, and as it builds up in the body, it can cause tremors, twitching, agitation, and seizures. A case report of a healthy 17-year-old who received standard doses of pethidine through a patient-controlled pump after surgery illustrates the risk: within 23 hours, he had a seizure, and blood tests showed both pethidine and norpethidine in the range associated with nervous system excitation.6PubMed. Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control This was not an overdose scenario or an unusually sensitive patient. It happened at standard doses in a healthy teenager, which underscores how narrow the safety margin is.
For someone addicted to pethidine who is using large amounts day after day, norpethidine builds up relentlessly. The seizure risk is cumulative. People with kidney problems are at even greater risk, because the metabolite’s already long elimination time stretches further, sometimes dramatically. This is one reason clinicians strongly advise against routine use of pethidine in anyone with compromised kidney function.7PubMed. Pharmacokinetics of opioids in renal dysfunction
Serotonin Syndrome Risk
Pethidine’s interaction with the serotonin system creates a second layer of danger that most other opioids do not share. Pethidine, along with tramadol and dextromethorphan, is classified as carrying a high risk of serotonin syndrome when combined with antidepressants that boost serotonin. Combining pethidine with monoamine oxidase inhibitors is outright contraindicated because of this interaction.8Prescriber Update. Opioids and serotonergic medicines: some combinations may increase the risk of serotonin syndrome
Serotonin syndrome can range from mild symptoms like shivering and diarrhea to life-threatening complications including high fever, muscle rigidity, and organ failure. For someone addicted to pethidine who also takes an antidepressant, this is not an abstract pharmacological curiosity. Given how common antidepressant prescriptions are, the overlap is a real clinical hazard. The risk also applies to other serotonergic drugs: certain migraine medications, herbal supplements like St. John’s Wort, and even some over-the-counter cough suppressants containing dextromethorphan.9Australian Prescriber. Opioids and antidepressants: which combinations to avoid
The serotonin transporter inhibition by pethidine occurs at concentrations close to those observed in normal clinical use, meaning you do not need to be using especially high doses for this interaction to become relevant.10PubMed Central. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome Someone in active pethidine addiction, taking much higher doses than a prescribed patient, faces an amplified version of this risk.
How Iatrogenic Addiction Happens
A disturbing feature of pethidine addiction is that it frequently starts in a hospital or clinic, prescribed by a doctor for a legitimate medical reason. Case reports describe patients who were started on pethidine for postoperative pain or chronic pain conditions and progressed to full dependence during the course of their treatment.11Dusunen Adam Journal of Psychiatry and Neurological Sciences. Venlafaxine Pharmacotherapy In Meperidine Addiction and Chronic Pain Comorbidity: A Case Report The term for this is iatrogenic addiction, meaning the medical system itself caused it.
The pattern tends to follow a predictable arc. A patient receives pethidine injections for acute pain. The drug works quickly and feels good. As tolerance builds over days, the patient needs higher or more frequent doses. By the time the underlying pain condition has been addressed, the patient has developed physical dependence. In one documented case, the patient’s prolonged high-dose pethidine use led to widespread physical complications including lower-limb swelling, poor wound healing, immune suppression, and surgical wound breakdown requiring further intervention.12International Archives of Addiction Research and Medicine. Iatrogenic Addiction Caused by Meperidine The addiction itself then became a medical problem layered on top of the original condition.
This kind of dependence has been documented rarely in the literature, partly because many cases are managed quietly during a hospital stay and partly because the shift away from pethidine prescribing has reduced the opportunity. But in settings where pethidine remains a standard analgesic, the risk is real, particularly for patients who need pain control for more than a few days.
Why Healthcare Workers Are Particularly Vulnerable
Pethidine has a long and well-documented history of misuse among doctors, nurses, and especially midwives and anesthetists. Healthcare workers have direct physical access to the drug, understand its effects, and can often self-administer without immediate detection. The literature on pethidine addiction going back to the 1950s flagged medical professionals as a group at elevated risk, and that pattern has continued through subsequent decades.
Midwives may be particularly exposed because pethidine remains one of the few injectable opioids they are authorized to administer independently in some healthcare systems. This combination of access, autonomy, and familiarity with the drug creates an environment where diversion, the practice of redirecting medication intended for patients to personal use, can occur with fewer barriers than might exist for other controlled substances in more tightly monitored settings.
The problem extends beyond access. Healthcare workers under stress who try pethidine may find its rapid onset and mood-altering serotonergic effects especially reinforcing. The shame and professional consequences of discovery can delay help-seeking, meaning that by the time the addiction is identified, it may be deeply entrenched.
Withdrawal and Its Complications
Pethidine withdrawal produces the classic opioid withdrawal syndrome: anxiety, restlessness, muscle aches, sweating, nausea, vomiting, diarrhea, and insomnia. Because pethidine is relatively short-acting, withdrawal symptoms tend to begin sooner after the last dose compared with longer-acting opioids like methadone, often within six to twelve hours.
There is an added wrinkle for people dependent on pethidine who are treated with the drug in emergency settings. A study comparing pethidine and morphine for acute pain in opioid-dependent patients found that those who received pethidine showed prominent withdrawal symptoms, with significantly higher withdrawal scores than those given morphine.13PubMed Central. Meperidine (pethidine) versus morphine in acute pain management of opioid-dependent patients This is partly because pethidine’s short duration and relatively weak opioid receptor binding at standard doses leave it unable to fully suppress withdrawal in someone who has built tolerance through heavier opioid use. For emergency physicians, this is a practical reason to choose morphine or another longer-acting opioid instead.
Treatment Approaches for Pethidine Dependence
Treating pethidine addiction follows the same general principles as treating other opioid dependencies, with a few pethidine-specific considerations. The first priority is usually converting the person from pethidine to a longer-acting opioid that does not produce a toxic metabolite. Methadone is the most common bridge: in the iatrogenic case described earlier, the patient was successfully transitioned from high-dose pethidine to methadone, which could then be managed on an outpatient basis.14International Archives of Addiction Research and Medicine. Iatrogenic Addiction Caused by Meperidine
Buprenorphine is another option that has gained favor for opioid dependence treatment more broadly. It has a large safety margin and can block the effects of other opioids, reducing the temptation to use on top of treatment.15PubMed. Pharmacological options for management of opioid dependence For someone coming off pethidine specifically, the switch to buprenorphine needs to be timed carefully. Starting buprenorphine too early, before pethidine has cleared enough, can precipitate withdrawal because of how buprenorphine interacts with opioid receptors.
Psychosocial support matters as much as the pharmacology. One case report described the use of venlafaxine, an antidepressant, as an adjunct in treating a patient with comorbid pethidine addiction and chronic pain.16Dusunen Adam Journal of Psychiatry and Neurological Sciences. Venlafaxine Pharmacotherapy In Meperidine Addiction and Chronic Pain Comorbidity: A Case Report This dual approach addresses the mood and pain components simultaneously, though any serotonergic antidepressant needs to be introduced only after the patient has been off pethidine long enough to avoid the serotonin syndrome risk discussed earlier.
Why Hospitals Have Been Dropping Pethidine
The combination of addiction potential, norpethidine toxicity, seizure risk, drug interactions, and the availability of safer alternatives has led many health systems to remove pethidine from their formularies or severely restrict its use. Clinicians have recommended these restrictions based on the accumulated evidence of adverse reactions and neurotoxicity.17Journal of Pain & Palliative Care Pharmacotherapy. Removing Meperidine from the Health-System Formulary—Frequently Asked Questions
Where restrictions have been implemented with institutional support, the results have been dramatic. One hospital that introduced a supported formulary restriction saw daily pethidine doses drop from about 38 per day, representing roughly a fifth of all injectable opioid doses, to less than one dose per day, essentially zero.18PubMed. Eliminating analgesic meperidine use with a supported formulary restriction Patient outcomes did not suffer because alternative analgesics filled the gap effectively. The transition revealed something important: much of the remaining pethidine use had been driven by habit and institutional inertia rather than genuine clinical need.
Alternatives that have replaced pethidine in most settings include morphine, fentanyl, hydromorphone, and increasingly non-opioid options like intravenous lidocaine for certain pain scenarios. A recent trial comparing intravenous lidocaine to pethidine for femoral fracture pain found that pethidine had a higher rate of adverse events.19PubMed Central. Comparing intravenous lidocaine and pethidine for pain management in emergency department patients with femoral bone fracture: a randomized controlled trial Findings like these reinforce the trend: for most clinical pain scenarios, something better and safer than pethidine is available.
Pethidine in Obstetrics
One setting where pethidine has lingered longer than others is labor and delivery. In many countries, pethidine remains an available option for pain relief during labor, sometimes the only injectable opioid midwives can give independently. This raises questions about both maternal addiction risk and effects on the newborn.
Research on newborns exposed to pethidine during labor found that higher cord blood levels of the drug were associated with babies who were drowsier, more prone to breathing difficulties immediately after birth, and showed reduced attention and social responsiveness in the days following delivery. Over the first six weeks, babies with higher exposure tended to be more irritable and less able to settle themselves. However, when compared with babies whose mothers received no drugs at all, the behavioral differences were relatively subtle and did not reach significance between the groups.20PubMed. The influence of maternal analgesia on neonatal behaviour: I. Pethidine
The addiction concern in obstetrics is less about the mother developing dependence from a single labor dose and more about the broader institutional pattern. When pethidine is the default labor analgesic, it stays embedded in clinical culture and supply chains, sustaining the kind of access and familiarity that facilitates diversion and misuse among staff. Some maternity units have moved to remifentanil patient-controlled analgesia or other alternatives precisely to reduce this institutional exposure.
Where Pethidine Remains Common and Why
Despite its declining use in high-income countries, pethidine remains widely available in parts of Africa, Asia, and the Middle East, where drug formulary choices are shaped by cost, supply chains, and regulatory frameworks that may not have caught up with the safety evidence. In some low-resource settings, pethidine may be one of very few injectable opioids reliably available, meaning clinicians face a genuine dilemma between using a drug with known risks and leaving patients in uncontrolled pain.
The continued availability in these settings means pethidine addiction remains a live problem globally, even as it becomes a historical footnote in countries that have phased it out. Healthcare workers in these regions face the same access-related risks that were documented decades ago in wealthier countries, often without the institutional safeguards, monitoring systems, or treatment infrastructure that would help catch and address emerging dependence early.
For patients in countries where pethidine is still prescribed routinely, awareness of the addiction risk is the most practical defense. If you are offered pethidine for pain after surgery or during a medical procedure, it is reasonable to ask whether an alternative is available. For short-term use lasting a day or two, the addiction risk is low though not zero. The danger ramps up sharply when use extends beyond a few days, especially if you find yourself wanting the drug for how it makes you feel rather than for pain relief. That shift in motivation is one of the earliest and most reliable warning signs of dependence taking hold.